Michael Dworzak
A5062188329- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Childhood Cancer Survivors' Quality of Life
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Lymphoma Diagnosis and Treatment
- Blood disorders and treatments
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Single-cell and spatial transcriptomics
- Hematological disorders and diagnostics
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Advanced biosensing and bioanalysis techniques
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Multiple Myeloma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- CAR-T cell therapy research
- Eosinophilic Disorders and Syndromes
- Cell Image Analysis Techniques
St. Anna Children's Cancer Research Institute
2011-2025
St Anna Children's Hospital
2016-2025
Medical University of Vienna
2016-2025
Community College of Rhode Island
1992-2024
Cancer Research Institute of the Slovak Academy of Sciences
2024
Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2018
Universidade Santa Úrsula
2017
TU Wien
2016
Charité - Universitätsmedizin Berlin
2016
Royal Hospital for Children
2015
Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present data obtained from 2345 leukemia patients. Genomic breakpoints within MLL involved translocation partner genes (TPGs) were determined 11 novel TPGs identified. Thus, a total 135 different have been identified so far, which 94 now characterized at molecular level. In all, 35 out these occur recurrently, but only 9 specific fusions account for...
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize chromosomal rearrangement individual leukemia patients. present data molecular characterization 1590 MLL-rearranged biopsy samples obtained from The precise localization genomic breakpoints within involved translocation partner genes (TPGs) were determined...
Speed of blast clearance is an indicator outcome in childhood acute lymphoblastic leukemia (ALL). Availability measurement minimal residual disease (MRD) at early time point with a reduced-cost method clinical relevance. In the AIEOP-BFM-ALL (Associazione Italiana Ematologia Oncologia Pediatrica and Berlin-Frankfurt-Münster Study Group) 2000 trial, patients were stratified by levels polymerase chain reaction (PCR) MRD day +33 +78. AIEOP studied prognostic impact measured flow cytometry (FCM)...
In pediatric relapsed acute myeloid leukemia (AML), optimal reinduction therapy is unknown. Studies suggest that liposomal daunorubicin (DNX; DaunoXome; Galen, Craigavon, United Kingdom) effective and less cardiotoxic, which important in this setting. These considerations led to a randomized phase III study by the International Berlin-Frankfurt-Münster Study Group.Patients with or primary refractory non-French-American-British type M3 AML who were younger than 21 years of age eligible....
Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in recent decades. However, it remained unknown whether advances first-line treatment, supportive care, or second-line therapy mainly contributed to this improvement. Here, we retrospectively analyzed outcome and clinical data 1940 AML (younger than 18 years age), enrolled the population-based AML-BFM trials between 1987 2012. While 5-year probability OS (pOS) from 49 ± 3% (1987–1992) 76 4% (2010–2012; p...
Sequencing of cell-free DNA in the blood cancer patients (liquid biopsy) provides attractive opportunities for early diagnosis, assessment treatment response, and minimally invasive disease monitoring. To unlock liquid biopsy analysis pediatric tumors with few genetic aberrations, we introduce an integrated genetic/epigenetic method demonstrate its utility on 241 deep whole-genome sequencing profiles 95 Ewing sarcoma 31 other sarcomas. Our achieves sensitive detection classification...
Abstract Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well therapy-induced infant, pediatric, and adult acute leukemias. Here, we present data obtained from 3401 leukemia patients that have been analyzed between 2003 2022. Genomic breakpoints within KMT2A involved translocation partner genes (TPGs) -partial tandem duplications (PTDs) were determined. Including published literature, a total 107 in-frame fusions identified so far. Further 16...
The International Berlin-Frankfurt-Münster (BFM) study group conducted a on pediatric acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) was assessed using flow cytometry (FCM), and the impact of early intensification methotrexate (MTX) dose survival evaluated.We included 6,187 patients younger than 19 years. MRD by FCM refined risk definition previously used in ALL intercontinental-BFM 2002 basis age, WBC count, unfavorable genetic aberrations, treatment response measured...
The rates of early death (ED) and treatment-related mortality (TRM) are unacceptably high in children undergoing intensive chemotherapy for acute myeloid leukemia (AML). Better strategies supportive care might help to improve overall survival these children.In a retrospective study, we analyzed incidence, clinical features, risk factors lethal complications 901 enrolled onto the multicenter trials Acute Myeloid Leukemia-Berlin-Frankfurt-Muenster (AML-BFM) 93 AML-BFM 98.One hundred four...
Because cytogenetic data are essential for risk stratification of childhood acute myeloid leukemia (AML), the impact chromosomal aberrations is crucial.Data a large group patients younger than 18 years treated according to study AML-Berlin-Frankfurt-Münster (BFM) 98 (n = 454), including their cytogenetics, were analyzed.The favorable outcome in subgroups with t(8;21), inv(16), and t(15;17), an overall survival 91% (SE, 4%), 92% 6%), 87% 5%), respectively, was confirmed. Within this group,...
To improve prognosis in children with acute myeloid leukemia (AML) by randomized comparisons of (1) two short consolidation cycles versus the Berlin-Frankfurt-Muenster (BFM) -type biphasic 6-week and (2) prophylactic administration granulocyte colony-stimulating factor (G-CSF) no G-CSF. Further, therapy for standard risk patients was intensified addition a second induction, HAM (high-dose cytarabine mitoxantrone).Four hundred seventy-three younger than 18 years de novo AML were enrolled...